Thursday, February 8, 2024 | Live Virtual Meeting
6:00 pm – 7:00 pm Pacific Time
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
by Perry Shieh, MD, PhD
Washington State Neurological Society cordially invites you to attend an CME/MOC-certified live webinar titled, “Spinal Muscular
Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies.”
This activity will Neurologists need to modify their clinical approach to provide individualized care within the context of new treatments. The number of adults with SMA is expected to continue to grow, and thus, a greater need exists for clinicians to improve their provision of age-appropriate care and ensure adults benefit from therapeutic advances. This educational initiative will provide targeted, clear, and concise information that would help neurologists provide optimal, individualized care to their adult patients with SMA.
Perry Shieh, MD, PhD
Departments of Neurology and Pediatrics
David Geffen School of Medicine at UCLA
University of California, Los Angeles
Los Angeles, California
For full accreditation information and to register:
♦ SMA overview, SMA type IV
♦ Disease burden, clinical and psychosocial impact
-Adult specific factors to consider – occupational/career, family planning
♦ Treatment options
-Safety and efficacy of available and emerging treatments for adults with SMA
◊ Risdiplam, nusinersen
◊ Clinical updates of note
– Psychosocial support for patients with SMA
♦ Factors to consider when developing/modifying treatment plans
-Goals, disease progression
-Patient engagement: How to foster this (shared decision-making, communication strategies)
Target Audience: The intended audience for this educational initiative is neurologists who manage patients with spinal muscular atrophy.
Upon completion of this activity, learners should be able to:
1.) Discuss the unique clinical issues and psychosocial needs faced by adults with SMA
2.) Assess the latest safety and efficacy data of available and emerging disease-modifying therapies for SMA in adults
3.) Integrate available disease-modifying therapies for SMA into individualized, evidence-based treatment plans
4.) Apply effective communication strategies to engage patients in shared decision making and reach management decisions that
meet their individual needs
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Cure
SMA. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide
continuing education for the healthcare team.
Disclosures will be made known to learners before the activity.
Provided by Clinical Care Options, LLC, in partnership with Cure SMA.
Supported by educational grants from Biogen and Genentech, a member of the Roche Group.